Tumor suppressor genes in human lung cancer

Journal of Medical Investigation

Volumn 44, Issue 1-2, 1997, Pages 15-24

  Shimizu, Eiji ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Lung cancer; P16; P53; RB; Tumor suppressor gene

Indexed keywords

GENETICS; HUMAN; HUMAN CHROMOSOME; LUNG TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS;

EID: 0031196254     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Nowell PC: The clonal evolution of tumor cell populations. Science 194: 23-28, 1976
2. Land H, Parada L, Weinberg R: Cellular oncogenes and multistep carcinogenesis. Science 222: 771-778, 1983
3. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T: Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 49: 6474-6479, 1989
4. Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, Mcbride OW, Bertmess V, Hollins GF, Minna JD; L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318: 69-73, 1985
5. Mugrauer G, Ekblom P: Contrasting expression patterns of three members of the myc family of protooncogenes in the developing and adult mouse kidney. J Cell Biol 112: 13-25, 1991
6. Birrer MJ, Segal S, Degreve JS, Kaye F, Sausville EA, Minna JD: L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol 8: 2668-2673, 1988
7. Rodenhuis S, van de Wetering M, Mooi W, Evers S, van Zandwijk N, Bos J: Mutational activation of the K-ras oncogene: A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935, 1987
8. Mitsudomi T, Viallet J, Mulshine J, Linoila RI, Minna J: Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small cell lung cancer cell lines, Oncogene 6: 1353-1362, 1991
9. Whang-Peng J, Bunn PA, Kao-Shan CS, Lee EC, Carney DN, Gazdar AF, Minna JD: A non-random chromosomal abnormality, del 3 p (14-23) in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 6: 119-124, 1982
10. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, Minna JD: Specific chromosome defect associated with human small cell lung cancer; deletion 3 p (14-23). Science 215: 181-182, 1982
11. Naylor SL, Johnson B, Minna J, Sakaguchi T: Loss of heterozygosity of chromosome 3 p markers in small cell lung cancer. Nature 329: 451-454, 1987
12. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T: Loss of heterozygosity on chromosomes 3, 13, and 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84: 9252-9256, 1987
13. Knudson AJ: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971
14. Knudson AJ: Genetics of human cancer. Annu Rev Genet 20: 231-251, 1986
15. Yunis JJ, Ramsay N: Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132: 161-165, 1978
16. Sparkes RS, Murphree AL, Lingua RW, Sparkes MC, Field LL: Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Science 219: 971-973, 1983
17. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646, 1986
18. Fung YKT, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF: Structural evidence for the authenticity of the human retinoblastoma gene. Science 236: 1657-1661, 1987
19. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EYHP: Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399, 1987
20. Gazdar AF, Oie HK: Call culture methods for human lung cancer. Cancer Genet Cytogenet 19: 5-10, 1986
21. Masuda N, Fukuoka M, Matsui K, Kusunoki Y, Kudoh S, Negoro S, Takihuji N, Fujisue M, Morino H, Nakagawa K, Nishioka M, Takada M: Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. J Natl Cancer Inst 83: 1743-1748, 1991
22. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y: Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 100: 429-438, 1991
23. Yoshida S, Shimizu E, Ogura T, Takada M, Sone S: Stimulatory effect of reconstituted basement membrane components (matrigel) on the colony formation of a panel of human lung cancer cell lines in soft agar. J Cancer Res Clin Oncol 123: 301-309, 1997
24. Kratzke RA, Shimizu E, Kaye FJ: Oncogenes in human lung cancer. Cancer Treat Res 63: 61-85, 1993
25. Morstyn G, Brown J, Novak U, Gardner J, Bishop J, Garson M: Heterogeneous cytogenetic abnormalities in small cell lung cancer cell lines. Cancer Res 47: 3322-3327, 1987
26. Miura I, Graziano S, Cheng J, Doyle A, Testa J: Chromosome alterations in human small cell lung cancer: Frequent involvement of 5q. Cancer Res 52: 1322-1328, 1992
27. Lukeis R, Irving L, Garson M, Hasthorpe S: Cytogenetics of non-small cell lung cancer: Analysis of consistent non-random abnormalities. Genes Chromosomes Cancer 2: 116-124, 1990
28. Whang-Peng J, Knutsen T, Gazdar A, Steinberg S, Oie H, Linnoila RI, Mulshine J, Nau M, Minna J: Nonrandom structural and numerical chromosome changes in non-small cell lung cancer. Genes Chromosomes Cancer 3: 168-188, 1991
29. Lee WH, Murphree AL, Benedict WF: Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309: 458-460, 1984
30. Harbour JW, Lai SL, Whang-Peng J, Gazder AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357, 1988
31. Yokota J, Akiyama T, Fung YKT, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T, Terada M: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475, 1988
32. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87: 2775-2779, 1990
33. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP: Point mutational inactivation of the retinoblastoma antioncogene. Science 243: 937-940, 1989
34. Kaye FJ, Kratzke RA, Grester JL, Horowitz JM: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 87: 6922-6926, 1990
35. Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S: Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 53: 494-504, 1996
36. Kratzke R, Shimizu E, Kaye FJ (unpublished)
37. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, Minna JD, Gazder AF, Kaye FJ: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994
38. Shimizu E, Zhao M, Shinohara A, Namikawa O, Ogura T, Masuda N, Takada M, Fukuoka M, Sone S: Differential expressions of cyclin A and RB protein in histological subtypes of lung cancer cell lines. J Cancer Res Clin Oncol (in press)
39. Ookawa K, Shiseki M, Takahashi R, Yoshida Y, Terada M, Yokota J: Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 8: 2175-2181, 1993
40. Kratzke RA, Shimizu E, Geradts J, Gerster JL, Segal S, Otterson GA, Kaye FJ: RB-mediated tumor suppression, of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Growth Differ 4: 629-635, 1993
41. Xu HJ, Sumegi J, Hu SX, Banerjee A, Uzvolgyi E, Klein G, Benedict WF: Intraocular tumor formation of RB reconstituted retinoblastoma cells. Cancer Res 51: 4481-4485, 1991
42. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ: Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene 8: 1913-1919, 1993
43. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C: Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 323: 1457-1462, 1990
44. Cordon CC, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1256, 1992
45. Logothetis CL, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256-1261, 1992
46. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51: 2735-2739, 1991
47. Shimizu E, Saijo N, Kanzawa F, Hoshi A, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Fujita J, Nomori H, Futami H, Miyazawa N: Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. Jpn J Cancer Res 75: 1030-1035, 1984
48. Shimizu E, Saijo N, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Fujita J, Nomori H, Hoshi A: Phase II study of oral administration of 5′-deoxy-5-fluorouridine (5′-DFUR) for solid tumors. Jpn J Clin Oncol 14: 679-683, 1984
49. Shimizu E, Mukai J, Takaue Y, Ogura T: Circulating hematopoietic progenitors in patients with primary lung cancer. Jpn J Cancer Res 81: 1293-1299, 1990
50. Shimizu E, Nakamura Y, Mukai J, Tani K, Yamashita T, Hojo F, Hashimoto Y, Ogura T: Pharmacokinetics of bronchial artery infusion of mitomycin in patients with non-small cell lung cancer. Eur J Cancer 27: 1046-1048, 1991
51. Shimizu E, Yamamoto A, Takahashi Y, Maniwa K, Yoshida S, Mukai J, Takaue Y, Ogura T: Effect of alternating combination chemotherapy containing cyclophosphamide, adriamycin, vincristine, cisplatin, and etoposide for small cell lung cancer on hematopoietic progenitors in peripheral blood. Br J Cancer 67: 798-800, 1993
52. Shimizu E, Ogura T, Sone S, Nakayama T, Doi H, Takishita T, Bando H, Kobayashi M, Kimura K, Sasaki H, Hashimoto T, Higuchi Y, Kawase I: Comparison of cisplatin plus vindesine with cisplatin plus mitomycin C for treatment of advanced non-small cell lung cancer. Oncology 50: 5-9, 1993
53. Lane DP, Crawford LV: T antigen is bound to a host protein in SV 40-transformed cells. Nature 278: 261-263, 1979
54. Linzer DI, Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52, 1979
55. Jenkins JR, Rudge K, Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312: 651-654, 1984
56. Finlay C, Hinds P, Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989
57. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989
58. Takahashi T, D'Amico D, Chiba I, Buchhagen DL, Minna JD: Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest 86: 363-369, 1990
59. Puisieux A, Lim S, Groopman J, Ozturk M: Selective targeting of p53 gene mutational hotspots in human lung cancers by etiologically defined carcinogens. Cancer Res 51: 6185-6189, 1991
60. INK4A gene. Int J Oncol 10: 33-39, 1997
61. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993
62. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994
63. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995
64. Chen PL, Scully P, Shew JY, Wang JYJ, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193-1198, 1989
65. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, Toyoshima K: Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci USA 89: 7900-7904, 1992
66. DeCaprio JA, Luldlow JW, Lynch D, Fukukawa Y, Griffin J, Piwinica-Worms H, Huang C-M, Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085-1095, 1989
67. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, T'Ang A, Fung YKT: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246: 1300-1303, 1989
68. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
69. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701-713, 1991
70. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993
71. Xiong Y, Connolly B, Futcher B, Beach D: Human D-type cyclin. Cell 65: 691-699, 1991
72. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cycle-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994
73. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006, 1992